Additionally, haptoglobin-conjugated nanoparticles and liposomes are under development for targeted drug delivery to inflamed tissues or cancer sites, aiming to maximise therapeutic efficacy while minimising systemic adverse effects (Aram et al., 2022). This evidence concerns the gene HP and cancer.